Dasatinib patent expiration date?

Dasatinib (Sprycel) has no single worldwide “patent expiration date”—it depends on which patent(s) and which country/region you mean (US, EU, UK, etc.). Generic manufacturers often launch only after the last relevant exclusivity/patent expires, and that can differ by jurisdiction.

If you tell me which country/region you care about (e.g., US vs EU), I can narrow it down to the relevant patent/exclusivity timeline.

Quick reference (general, not legal advice):

• United States (US): generic availability for dasatinib has generally followed the expiration/expiry of key exclusivity/patents plus any relevant extensions. In practice, generic versions have already launched in many cases, but the exact “expiration date” is a specific legal question tied to particular patents.
• European Union/UK: timelines can differ due to separate national procedures and granted patents, and later “day” may be driven by the last granted right.

To answer precisely, please reply with:

1. Country/region (US / EU / UK / other)
2. Whether you mean first generic launch date or the legal last patent/exclusivity expiry date
3. (Optional) If you have a specific patent number or “Orange Book” entry (US) / EP number (EU), share it.